Recent investigations into retatrutide, a dual agonist for GLP-1 and GIP receptors, are revealing promising outcomes in treating obesity and diabetes non-insulin-dependent disease. Preclinical information suggest a https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/